2014
DOI: 10.1128/ec.00191-14
|View full text |Cite
|
Sign up to set email alerts
|

Off-Target Effects of the Septin Drug Forchlorfenuron on Nonplant Eukaryotes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
29
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 31 publications
(29 citation statements)
references
References 68 publications
0
29
0
Order By: Relevance
“…A recent study demonstrated that FCF alters mitochondrial morphology (61). Based on this observation, the authors suggested the existence of non-septin targets of FCF, but no such targets have been identified (61). Moreover, no evidence has been presented that the morphological changes in mitochondria are independent of the FCF-induced impairment of assembly and disassembly of septins that are known to reside in mitochondria (62).…”
Section: Septin-containing Protein Complexes Undergo Continuous Reorgmentioning
confidence: 94%
See 1 more Smart Citation
“…A recent study demonstrated that FCF alters mitochondrial morphology (61). Based on this observation, the authors suggested the existence of non-septin targets of FCF, but no such targets have been identified (61). Moreover, no evidence has been presented that the morphological changes in mitochondria are independent of the FCF-induced impairment of assembly and disassembly of septins that are known to reside in mitochondria (62).…”
Section: Septin-containing Protein Complexes Undergo Continuous Reorgmentioning
confidence: 94%
“…4, 7C, and 8D). A recent study demonstrated that FCF alters mitochondrial morphology (61). Based on this observation, the authors suggested the existence of non-septin targets of FCF, but no such targets have been identified (61).…”
Section: Septin-containing Protein Complexes Undergo Continuous Reorgmentioning
confidence: 99%
“…3B). To date the only known septin inhibitor is FCF , but its specificity is questionable and off-target effects have recently been described (Heasley et al, 2014). It will therefore be necessary to develop systems to screen for novel cellpermeable septin inhibitors that alter septin filament structure and inhibit cytokinesis of only the targeted cell types.…”
Section: Septin Inhibitors As Directed Therapy Against Solid Tumorsmentioning
confidence: 99%
“…Both siRNA knockdown of septin-2/septin-9 and inhibition of septin filament assembly-disassembly with FCF induce ErbB2 degradation (Fig. 4A), confirming that degradation of ErbB2 is a result of interference with septin dynamics rather than an unknown, alternate target of FCF [72]. By re-organizing septin oligomers, FCF disrupts ErbB2-septin complexes at the plasma membrane and induces internalization and degradation of ErbB2.…”
Section: Discussionmentioning
confidence: 62%